Weekly injections for weight management in teenagers with genetic obesity

This study is observing how semaglutide, a once-weekly injectable medication, helps teenagers with monogenic obesity (obesity caused by changes in specific genes) lose weight. Participants will use the medication alongside a reduced-calorie diet and increased physical activity over 68 weeks. The researchers want to understand how well this treatment works in real-world clinical practice and how it affects hunger, mood, and overall quality of life.

Monogenic obesity is a rare genetic condition where specific gene changes make weight loss extremely difficult through diet and exercise alone. This medication has shown promise in adults, but there is limited information about how well it works and how safe it is for teenagers with this specific genetic form of obesity.